HTGC - Hercules Capital, Inc. Последние новости | Finranks

17.06.2026

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

- Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has entered into an amendment to its non-dilutive senior secured term loan facility with Hercules Capital, Inc. (NYSE: HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets.

16.06.2026

Hercules Capital (HTGC) Ascends While Market Falls: Some Facts to Note

Hercules Capital (HTGC) closed the most recent trading day at $15.65, moving +1.03% from the previous trading session.

10.06.2026

Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Beren Therapeutics P.B.C., the parent company of Mandos LLC and a leader in cholesterol trafficking biology and cyclodextrin-based therapeutics, today announced it has secured $300 million in combined financing. The financing includes a $135 million equity financing alongside up to $165 million in a strategic financing facility with Hercules Capital, Inc. (NYSE: HTGC) across a senior secured debt and royalty structure. Capital will support Beren's growth.

09.06.2026

Hercules Capital: Attractive Valuation And Growth Potential

Hercules Capital is a strong buy, trading at a rare 28.4% NAV premium versus its 5-year average of 49.36%. HTGC offers a 12.3% dividend yield, with distributions well covered by net investment income and supported by $149.1M in spillover income. The portfolio is conservatively structured, with 98% floating-rate senior secured loans and non-accruals at just 0.1% of fair value.

04.06.2026

Hercules Capital (HTGC) Down 7.4% Since Last Earnings Report: Can It Rebound?

Hercules Capital (HTGC) reported earnings 30 days ago. What's next for the stock?

27.05.2026

My Dividend Stock Portfolio: New April Dividend Record - 100 Holdings With 5 Buys

April net investment activity reached a multi-year low as rising stock valuations and BDC sector weakness prompted a cautious approach and selective BDC purchases. Focused April allocations on Ares Capital, Blue Owl Capital, and Hercules Capital, yielding a 7.5% average on new investments despite sector headwinds. Dividend income set a modest April record at $990, up 3% year-over-year, with BDCs contributing 27% of Q2 year-to-date dividends but facing potential further cuts.

24.05.2026

The High-Yield Stocks the Smart Money Is Buying Right Now

There is a principle I have followed for 30 years in this business. When the smartest credit team on the planet starts aggressively buying a beaten-down asset class they understand better than anyone alive, you do not sit on your hands and debate whether the timing is perfect.

Видео

No Data

There is no data to display

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
HTGC	Piper Sandler	Neutral	undefined >> $18	February 13th 2026

Пресс-релизы

17.06.2026

Hercules Capital, Inc. (HTGC)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Hercules Capital, Inc. (HTGC)

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

Hercules Capital (HTGC) Ascends While Market Falls: Some Facts to Note

Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C

Hercules Capital: Attractive Valuation And Growth Potential

Hercules Capital (HTGC) Down 7.4% Since Last Earnings Report: Can It Rebound?

My Dividend Stock Portfolio: New April Dividend Record - 100 Holdings With 5 Buys

The High-Yield Stocks the Smart Money Is Buying Right Now

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C

HTGC DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Hercules Capital, Inc. Investors to Secure Counsel Before Important May 19 Deadline in Securities Class Action - HTGC

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hercules Capital, Inc. of Class Action Lawsuit and Upcoming Deadlines – HTGC

Search stocks

Hercules Capital, Inc. (HTGC)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Hercules Capital, Inc. (HTGC)

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

Hercules Capital (HTGC) Ascends While Market Falls: Some Facts to Note

Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C

Hercules Capital: Attractive Valuation And Growth Potential

Hercules Capital (HTGC) Down 7.4% Since Last Earnings Report: Can It Rebound?

My Dividend Stock Portfolio: New April Dividend Record - 100 Holdings With 5 Buys

The High-Yield Stocks the Smart Money Is Buying Right Now

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C

HTGC DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Hercules Capital, Inc. Investors to Secure Counsel Before Important May 19 Deadline in Securities Class Action - HTGC

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hercules Capital, Inc. of Class Action Lawsuit and Upcoming Deadlines – HTGC